Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.47 |
| ▸ | EBP | Q15125 | 1/20 | 0.47 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | USP5 | P45974 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749559 | 0.99 | KDM4E (0.63) | KDM4EGAAL3MBTL3ALDH1A1MBTD1 | |
| SCHEMBL6003121 | 0.85 | TSHR (0.53) | KDM4EGAAALDH1A1HPGDCYP2C19 | |
| SCHEMBL5146481 | 0.83 | TSHR (0.56) | KDM4EGAAALDH1A1HPGDCYP2C19 | |
| SCHEMBL3982616 | 0.81 | TSHR (0.48) | GAAALDH1A1HPGDCYP2C19MEN1 | |
| SCHEMBL14811388 | 0.76 | MEN1 (0.58) | GAAALDH1A1MEN1KMT2A | |
| SCHEMBL5657049 | 0.74 | L3MBTL1 (0.43) | GAAALDH1A1CYP2C19L3MBTL1 | |
| SCHEMBL6745871 | 0.74 | POLB (0.57) | ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL6749538 | 0.74 | ALDH1A1 (0.44) | GAAALDH1A1CYP2D6CYP2C19KMT2A | |
| SCHEMBL1855017 | 0.74 | KMT2A (0.51) | GAAALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL5438658 | 0.74 | PKM (0.49) | KDM4EALDH1A1CYP2D6CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730783-B2 | REACTING AMINOGUANIDINE WITH CARBONYL COMPOUND TO FORM AMIDINOHYDRAZONE; REDUCTION; REACTING WITH ALKOXYAMINE; GUANIDINYLATION; ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-05-04 | — | — | US | disclosed |
| US-6706765-B2 | ESPECIALLY TRYPSIN-LIKE SERINE PROTEASES, SUCH AS CHYMOTRYPSIN, TRYPSIN, THROMBIN, PLASMIN AND FACTOR XA. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-01 | — | — | US | disclosed |
| US-6635637-B2 | Cyclic oxyguanidine derivatives useful as enzyme inhibitors, and particularly to a new class of non- peptidic inhibitors of proteolytic enzymes; treats pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema and inflammation | DIMENSIONAL PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| EP-1307432-A1 | CYCLIC OXYGUANIDINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-05-07 | — | — | EP | disclosed |
| US-6518310-B2 | Non-peptidic; inhibits trypsin-like protease, thrombin and embolus formation; anticoagulant | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-11 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020022615-A1 | Cyclic oxyguanidine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2002012207-A1 | CYCLIC OXYGUANIDINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002539-A1 | Process for preparing aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | KDM4E 1568/4885GAA 402/4885L3MBTL3 1673/4885 |
| US-20030158252-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | PLG, MMP9, F9 | KDM4E 1353/4885GAA 389/4885L3MBTL3 1740/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | KDM4E 1260/4885GAA 366/4885L3MBTL3 1822/4885 |
| US-20020022615-A1 | Cyclic oxyguanidine protease inhibitors | PLG, TFPI, PLAT | KDM4E 2255/4885GAA 275/4885L3MBTL3 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.